COVID-19 Sample Collection and Vaccine Studies

NIH Pandemic-Era Grants

Pandemic Era Grants

2021

↗ Live URL (may be dead)

Document text

Principal Investigator: Julie E. Ledgerwood
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2021
Award: $485,881
Funding agency: National Institute of Allergy and Infectious Diseases

The evaluation of a vaccine candidate targeting COVID-19 and collection of samples to support translational immunology research support the broader VRC mission.  For this project, sample collection was conducted under the VRC 200 protocol while the evaluation of an investigational vaccine candidate was conducted under the DMID 20-0003 protocol. 

VRC 200: A Multicenter Specimen Collection Protocol to Obtain Human Biological Samples for Research Studies

DMID 20-0003: Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults

Terms: <2019-nCoV vaccine><21+ years old><Adult><Adult Human><Assay><Bioassay><Biologic Assays><Biological><Biological Assay><COVID-19><COVID-19 infection><COVID-19 vaccine><COVID19><COVID19 infection><COVID19 vaccine><CV-19><CV19><Cellular Immune Function><Development><Dose><Evaluation><Human><Immune response><Immunity><Immunological response><Immunology><Individual><Investigation><Measures><Mission><Modern Man><Moderna COVID-19 vaccine><Moderna coronavirus disease 2019 vaccine><Phase><Preventive><Protocol><Protocols documentation><Research><Research Support><SARS-CoV-2 infection><SARS-CoV-2 vaccine><SARS-CoV2 infection><SARS-CoV2 vaccine><SARS-coronavirus-2 vaccine><Safety><Sampling><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 vaccine><Severity of illness><Therapeutic><adulthood><corona virus disease 2019><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 infection><coronavirus disease 2019 vaccine><developmental><disease severity><host response><immune function><immune system response><immunogenicity><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><mRNA-1273><mRNA1273><open label><open label study><research study><safety study><sample collection><specimen collection><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidate><vaccine for novel coronavirus><vaccine study><vaccine trial>